Sandra Peiró

Head of the Chromatin Dynamics in Cancer Group

Vall d'Hebron Institute of Oncology
Country flagSpain
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.

Year:

2025

Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.

Year:

2025

Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.

Year:

2025

Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.

Year:

2025

Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.

Year:

2025

Collaborators (13)

Anthony Turpin

Centre Hospitalier Régional Universitaire de Lille

FRANCE
View details

Joaquin Arribas

Research Director

Hospital del Mar

SPAIN
View details

Ana Vivancos

Principal Investigator

Vall d'Hebron Institute of Oncology

SPAIN
View details

ENRIQUE JAVIER ARENAS LAHUERTA

Institute for Research in Biomedicine

SPAIN
View details

Winona Oliveros

KTH Royal Institute of Technology

SWEDEN
View details

Cindy Neuzillet

PU PH

Université de Versailles Saint-Quentin-en-Yvelines

FRANCE
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Marta Mele

Group leader

Barcelona Supercomputing Center

SPAIN
View details

Oscar Pozo

Miguel Servet II

Institut Hospital del Mar d'Investigacions Mèdiques

SPAIN
View details

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Clínic de Barcelona

SPAIN
View details

Paolo Nuciforo

Head

Vall d´Hebron Institut d´Oncologia

SPAIN
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

TIAN TIAN

Vall d'Hebron Institute of Oncology

SPAIN
View details